A Biomimetic Adiponectin–Extracellular Vesicle (APN-EV) Combined with GLP-1: Efficacy in Preclinic
- Introducing APN-EV, the first stable, functional multimeric adiponectin, to improve insulin sensitivity and drive fat clearance
- Demonstrating synergistic fat loss with microdose APN-EV and GLP-1R agonists to enhance efficacy while preserving muscle mass and address the sarcopenia challenges associated with incretin-based therapies
- Exploring the translational and commercial potential of the EV platform, including manufacturing scalability, cost-of-goods advantages